ESPR - Company ID 0001434868
The table below shows Esperion Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $403.13M | $332.31M | $116.33M | $75.47M | $78.45M | $227.55M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $165.79M |
Esperion Therapeutics, Inc. reported annual revenue of $403.13M for fiscal year 2025. That is up 21.3% from $332.31M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $163.07M |
| $142.52M |
| $109.08M |
| $184.99M |
| $199.62M |
| Operating income | $60.27M | $54.40M | -$155.56M | -$179.50M | -$226.73M | -$121.40M |
| Income tax | $1.84M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$22.68M | -$51.74M | -$209.25M | -$233.66M | -$269.11M | -$143.55M |
| EPS (diluted) | -$0.11 | -$0.28 | -$2.03 | -$3.52 | -$9.31 | -$5.23 |